Impact BioMedical Inc., a wholly owned subsidiary of Document
Security Systems Inc. (NYSE American: DSS), today announced it was
issued a patent (Patent # 11,033,528) on June 15, 2021, from the
U.S. Patent and Trademark Office for its proprietary compound
Equivir. This is a follow-up to the release on April 6, 2021, for
the allowance of this patent. The compound has displayed positive
pre-clinical results that reduce the risk and/or severity
attributable to viral infections, specifically Ebola and
Rhinovirus.
This patent is the second issued to Impact BioMedical for
Equivir; the first (Patent # 10,383,842) was issued August 20,
2019, with claims directed to a method of limiting the occurrence
of, reducing the risk or severity of, or treating influenza
infection.
“This is the second patent for Equivir and expands Impact
BioMedical’s intellectual properties in this area,” said Frank D.
Heuszel, CEO of DSS. “We are seeking a third patent for Equivir,
with the hope of expanding its potential in a variety of antiviral
applications and providing long-term value.”
Mr. Chan Heng Fai, the Chairman of Document Security Systems,
who owns Impact BioMedical, said that today’s announcement
highlights Equivir’s potential versatility. “We are pleased to
receive this second patent and are excited to explore the potential
and long-term impact that Equivir can have on the way we treat and
defend against these viruses.”
Equivir is believed to function by impeding a virus’s ability to
infect and replicate in host cells. Taken much like a multivitamin,
Equivir was specifically designed for ease of rapid accessibility
and deployment. Pre-clinical in-vitro success showed Equivir is
potentially useful for pandemics and viral outbreaks against
SARS-COV2, Influenza, Ebola, Cholera, and Rhinovirus.
Ebola, also known as Ebola Virus Disease (EVD) or Ebola
Hemorrhagic fever (EHF), is a rare but severe and often fatal
illness in humans, particularly in sub-Saharan Africa. Ebola has a
death rate of up to 90 percent, according to the World Health
Organization. Rhinovirus is the most common viral infectious agent
in humans and is the predominant cause of the common cold.
“Equivir is designed to address emerging viral epidemics and
pandemics. This latest patent will support our research to explore
Equivir as a deployable strategic defense for a broad spectrum of
viral infections,” said Daryl Thompson, Impact BioLife's Director
of Scientific Initiatives and founder of advanced research company
GRDG Sciences, LLC ("GRDG"). Impact BioLife is a wholly owned
subsidiary of Impact BioMedical.
The positive results achieved from initial studies makes it
potentially valuable around the world, according to GRDG Chief
Scientific Advisor Dr. Roscoe M. Moore, Jr., United States
Assistant Surgeon General (Retired) and former Epidemic
Intelligence Service (EIS) Officer at the Centers for Disease
Control and Prevention. “We will continue to study the ways Equivir
can lessen the severity of dangerous pathogens that affect
populations all over the world. Whether it is used alongside other
medications, or becomes the basis of its own therapeutic regimen,
we are hopeful that Equivir can play a central role in impeding the
spread of viruses,” said Dr. Moore.
Impact BioMedical reports that it has a third Equivir patent
pending which contains claims directed to a method of limiting the
occurrence of, reducing the risk or severity of, or treating other
viral infections. Impact BioMedical has also completed a research
study which evaluated the potential effectiveness of Equivir in
in-vitro studies inhibiting viral infections including
SARS-COV2.
About Impact BioMedical, Inc. Impact
BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary
of DSS. Impact BioMedical strives to leverage its scientific
know-how and intellectual property rights to provide solutions that
have been plaguing the biomedical field for decades. By tapping
into the scientific expertise of GRDG Sciences, LLC, Impact
BioMedical pledges to undertake a concerted effort in the R&D,
drug discovery and development for the prevention, inhibition, and
treatment of neurological, oncological and immuno related diseases.
For more information on Impact BioMedical visit
http://impbio.com/.
About Document Security Systems, Inc. DSS is a
multinational company operating businesses focused on brand
protection technology, blockchain security, direct marketing,
healthcare, real estate, and securitized digital assets. Its
business model is based on a distribution sharing system in which
shareholders will receive shares in its subsidiaries as DSS
strategically spins them out into IPOs. Its historic business
revolves around counterfeit deterrent and authentication
technologies, smart packaging, and consumer product engagement. DSS
is led by its Chairman, Mr. Fai Chan, a highly successful global
business veteran of more than 40 years specializing in corporate
transformation while managing risk. He has successfully
restructured more than 35 corporations with a combined value of $25
billion.
For more information on DSS visit
http://www.dsssecure.com.
Investor Contact:Dave Gentry, CEORedChip Companies
Inc.407-491-4498Dave@redchip.com
Safe Harbor Disclosure This press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Such forward-looking
statements include, but are not limited to, statements related to
the Company's intended use of proceeds and other statements that
are not historical facts. Forward-looking statements are based on
management's current expectations and are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. These risks and uncertainties,
many of which are beyond our control, include: risks relating to
our growth strategy; our ability to obtain, perform under and
maintain financing and strategic agreements and relationships;
risks relating to the results of development activities; our
ability to attract, integrate and retain key personnel; our need
for substantial additional funds; patent and intellectual property
matters; competition; as well as other risks described in our SEC
filings, including, without limitation, our reports on Forms 8-K,
10-K and 10-Q, all of which can be obtained on the SEC website at
www.sec.gov. Readers are cautioned not to place undue reliance on
the forward-looking statements, which speak only as of the date on
which they are made and reflect management's current estimates,
projections, expectations, and beliefs. We expressly disclaim any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in our expectations or any changes in events,
conditions, or circumstances on which any such statement is based,
except as required by law.
DSS (AMEX:DSS)
Historical Stock Chart
From Aug 2024 to Sep 2024
DSS (AMEX:DSS)
Historical Stock Chart
From Sep 2023 to Sep 2024